Test dose-dense chemo before surgery for high-growth hormone-positive breast cancer
Part of Cancer, Skin clinical trials.
This Phase 2 study tests a faster, more frequent chemotherapy schedule given before surgery (neoadjuvant therapy) for certain breast cancers that grow quickly. It may help shrink the tumor before the operation and improve treatment response in people who fit the tumor and health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 70 and were newly diagnosed with breast cancer
- Your tumor is ER-positive or PR-positive, and HER2 is negative
- Your tumor has a high growth score (Ki-67 of 30% or higher)
- Your breast cancer is in stages IIB to IIIC (not metastatic or spread to distant organs)
- You plan to receive chemotherapy before surgery (neoadjuvant chemotherapy), and you can do follow-up visits
- Your overall strength is good (ECOG 0 to 1) and your blood counts, liver, kidneys, and heart function meet safety limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
This Phase 2 trial compares nab-PH plus pyrrolitinib versus TCbHP as treatment given before breast surgery. It aims to see which option works better and is safe for people with HER2-positive invasive breast cancer.
This trial tests a treatment given before breast surgery to shrink breast cancer and improve outcomes based on your tumor type. Your eligibility depends on tumor size/stage, hormone and HER2 markers, and overall health checks.
This trial compares two different drug combinations given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see which combination works better and has fewer side effects.
This study compares an “albumin-bound” form of paclitaxel versus other taxane chemotherapy options after breast surgery. It’s for people with HER2-negative, higher-risk breast cancer to see which approach works better in real-world care.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.